Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph, Inc
Neomorph, Inc
Bristol-Myers Squibb
Allogene Therapeutics
Osel, Inc.
Mabpro, a.s.
Bristol-Myers Squibb
Celldex Therapeutics
Celldex Therapeutics